DHAP (chemotherapy)

This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.
Find sources: "DHAP" chemotherapy – news · newspapers · books · scholar · JSTOR (May 2021)

|

Medical intervention

DHAP

Specialty| Oncology

[edit on Wikidata]

DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.

[R]-DHAP regimen consists of:

1. Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
2. Dexamethasone, a glucocorticoid hormone
3. High-dose Ara-C - cytarabine, an antimetabolite;
4. Platinol  (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.

## Dosing regimen

[edit]

Drug | Dose | Mode | Days

|
|
|

Rituximab | 375 mg/m2 | IV infusion | Day 0
Dexamethasone | 40 mg | PO qd | Days 1-4
High-dose Ara-C - cytarabine | 2000 mg/m2 | IV infusion over 2 hrs | Day 2, every 12 hours
Platinol (cisplatin) | 100 mg/m2 | IV infusion over 24 hrs | Day 1

## References

[edit]

1. ^ Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)